Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21046947 | 0.86 | VNN1 (0.64) | VNN1MAPTGAATHRBHDAC6 | |
| SCHEMBL2392295 | 0.85 | VNN1 (0.62) | VNN1MAPTGAAHDAC6NPC1 | |
| SCHEMBL5622343 | 0.82 | VNN1 (0.59) | VNN1MAPTGAANPC1RAB9A | |
| SCHEMBL3669945 | 0.82 | NPC1 (0.63) | VNN1MAPTGAATHRBHDAC6 | |
| SCHEMBL12674818 | 0.82 | VNN1 (0.63) | VNN1MAPTGAAHDAC6NPC1 | |
| SCHEMBL25934368 | 0.81 | VNN1 (0.62) | VNN1HDAC6 | |
| SCHEMBL25934345 | 0.81 | VNN1 (0.57) | VNN1MAPTGAANPC1RAB9A | |
| SCHEMBL27429524 | 0.81 | VNN1 (0.61) | VNN1MAPTGAANPC1RAB9A | |
| SCHEMBL21056224 | 0.80 | VNN1 (0.57) | VNN1MAPTGAATHRBHDAC6 | |
| SCHEMBL25934308 | 0.79 | VNN1 (0.52) | VNN1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | VNN1 4618/4885MAPT 1315/4885GAA 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.